Impact ledger
iBio, Inc. (IBIO): the developments shaping its investment case
Follow the evidence affecting iBio, Inc.'s capital spending, valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-28 | capex | Bullish | Increased spending on R&D and CMC activities for clinical-stage programs IBIO-600 and IBIO-610. |
| 2026-08-28 | multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. |
| 2026-08-28 | share_count | Bullish | Primary equity issuance increases diluted share count. |
Event impact log
3 events mapped to IBIO since 2026-08-27. Evidence through 2026-08-28.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-08-28 | iBio, Inc. ATM — $100M | Direct equity dilution and potential downward pressure on share price due to increased supply. | Bearish | 1-3m | 0.80 |
| 2026-08-28 | iBio, Inc. Follow-On — $100M | Direct equity dilution and capital infusion for operations. The 'Open Market Sale Agreement' suggests a controlled, 'at-the-market' offering, which can spread dilution over time but still introduces selling pressure. | mixed | 1-3m | 0.80 |
| 2026-08-27 | Interpace Biosciences Announces 1-for-5 Reverse Stock Split for Nasdaq Uplisting | Direct corporate action to maintain exchange listing and potentially improve stock perception. While it addresses a technical requirement, it doesn't fundamentally change the company's underlying value or operational performance. | mixed | 1-3m | 0.70 |
Continue this research
Build your iBio, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the IBIO entity page →